AgroAmerica Ranks Among the Top 10 of the Most Transparent Companies in Sustainable Palm Oil Practices in the World
10.11.2020 20:47:00 EET | Business Wire | Press release
AgroAmerica ranked as the 7th sustainable company out of 100 oil palm companies in the world. This year the company received a rating of 84.95% in the latest Sustainability Policy Transparency Toolkit (SPOTT) Assessment recently released by the UK-based Zoological Society of London (ZSL).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201110006035/en/
AgroAmerica ranked in the top 10 out of 100 palm oil producers, processors, and traders on the public disclosure of their policies, operations, and commitments to environmental, social, and governance (ESG) best practice, in the results published by the renowned SPOTT Transparency evaluation. On the image, one of the most notable AgroAmerica's conservation project, The Maya Biosphere Conservation Project, that promotes the protection of 19,000+ hectares of land and the biodiversity of the area. (Photo: Business Wire)
The SPOTT platform promotes the transparency of companies by disclosing their policies, practices, and commitments related to environmental, social, and governance issues.
Fernando Bolaños, CEO of AgroAmerica, said that this is the third consecutive year that AgroAmerica participates in this sustainability evaluation, intending to improve, year after year, its practices and commitments, and continue to offer food products sustainably produced and distributed.
SPOTT evaluates 180 indicators grouped into 10 categories: Sustainability and leadership; Landbank, maps and traceability; Certification standards; Deforestation and biodiversity; HCV, HCS and impact assessments; Peat, fire and GHG emissions; Water, chemical and pest management; Community, land and labor rights; Smallholders and suppliers; Governance and grievances.
The evaluation aims to measure the progress of companies towards sustainable production and marketing of palm oil. Among the most notable results, AgroAmerica obtained the complete qualification in HCV, HCS and impact assessments, for its commitment to the conservation of ecosystems, especially in areas of High Conservation Value.
Additionally, its commitment to zero deforestation and the use of technological tools for the optimization of natural resources, as well as the implementation of programs and projects for compliance with labor and land rights and the verifiable establishment of good relations with communities, allowed AgroAmerica to be among the top 10 of the companies evaluated in the transparency ranking.
The SPOTT evaluation team, comprised of professionals from prestigious London universities, belongs to ZSL, and is part of the Palm Oil Roundtable (RSPO).
“Participating in this evaluation is part of our policy of being transparent in our sustainable production practices and reaffirming our commitment to comply with international standards, which leads us to differentiate ourselves and have a competitive advantage in the oil palm sector, as well as promote a sustainable production and trade, ”stated Bolaños.
About AgroAmerica
AgroAmerica is an agro-industrial company dedicated to the production and commercialization of food products, through sustainable and responsible methods. Our company has operations in Europe, the United States, Mexico, Guatemala, Ecuador, Peru, and Panama.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201110006035/en/
Contact information
Javier Aguirre
Corporate Director
comunicacion@agroamerica.com
(502) 2420-9600
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Organon to Present New Research on Access and Value at ISPOR 202615.5.2026 14:30:00 EEST | Press release
Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, will present data across women’s health, biosimilars, dermatology, and neurology at ISPOR 2026, the leading global scientific conference hosted by the International Society for Pharmacoeconomics and Outcomes Research. The conference, focused on health economics and outcomes research, will take place May 17-20, 2026, in Philadelphia, Pennsylvania. Across 8 accepted abstracts, the data reflect Organon’s commitment to generating real-world evidence—rooted in lived experiences—that can help inform healthcare decision-making and improve health outcomes across a range of therapeutic areas. “Health economics and outcomes research is critical to ensuring the right treatments reach patients and that health systems can sustain this approach over time,” said Juan Camilo Arjona Ferreira, MD, Head of R&D and Chief Medical Officer at Organon. “At ISPOR 2026, Organon
SES Announces Extraordinary General Meeting of Shareholders15.5.2026 09:30:00 EEST | Press release
SES: Société Anonyme RCS Luxembourg B 81267 Notice is hereby given of the Extraordinary General Meeting of SES, Société Anonyme, to be held at the Company's registered office at Château de Betzdorf, L-6815 Betzdorf (the "Company"), Luxembourg, on Wednesday 17 June 2026 at 3:00 p.m. CET AGENDA Attendance list, quorum and adoption of the agenda Nomination of a secretary and of two scrutineers Cancellation of shares purchased in connection with the buy-back programme of 2 November 2023, as amended on 2 May 2024, in accordance therewith and pursuant thereto - Reduction of the share capital in accordance with article 450-5 of the law of 10 August 1915 on commercial companies, as amended, by forty-four million nine hundred ten thousand seven hundred eighty euro (EUR 44,910,780) through the cancellation of thirty-five million nine hundred and twenty-eight thousand six hundred and twenty-four (35,928,624) shares divided into (i) twenty-three million nine hundred and fifty-two thousand four hun
Experian Partners With ServiceNow to Scale Trusted Decisioning to Agentic AI15.5.2026 09:00:00 EEST | Press release
Experian, the global data and technology company, and ServiceNow (NYSE: NOW), the AI control tower for business reinvention, today unveil a new global multi-year partnership which harnesses the power of autonomous AI agents across platforms, helping businesses make faster and smarter decisions at scale. Through this partnership, autonomous AI agents can gain the ability to act faster, and more consistently, starting with employee onboarding, third-party risk management and model life cycle governance use cases. A major challenge for global organisations adopting agentic AI is achieving scale, with deployments often constrained by a lack of trusted data. In fact, industry research shows that data limitations are the primary barrier for eight in ten organisations. By connecting trusted intelligence directly into enterprise workflows, this partnership enables agentic AI to scale well beyond pilot deployments. With the Experian Ascend Platform natively connected to the ServiceNow AI Platfo
Meiji Seika Pharma: Positive Results from the Phase III Integral-1 Trial of Nacubactam, a Novel β-Lactamase Inhibitor, in Complicated Urinary Tract Infections or Acute Uncomplicated Pyelonephritis ― Published in The Lancet15.5.2026 04:00:00 EEST | Press release
Meiji Seika Pharma Co., Ltd. (headquartered in Tokyo; President and Representative Director: Toshiaki Nagasato) today announced that the results of the Integral-1 study, one of two global Phase III clinical trials evaluating the efficacy and safety of its novel β-lactamase inhibitor nacubactam (development code: OP0595), have been published in The Lancet. The article is entitled “---Efficacy and safety of cefepime–nacubactam and aztreonam–nacubactam compared with imipenem–cilastatin for complicated urinary tract infection or acute uncomplicated pyelonephritis (Integral-1): a double-blind, randomised phase 3 trial” (https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)00596-9/fulltext) Integral-1 is a global, double-blind, randomized Phase III trial (jRCT2031230075) in patients with complicated urinary tract infection or acute uncomplicated pyelonephritis that compared the efficacy and safety of nacubactam co-administered with either cefepime or aztreonam versus imipenem-c
Xsolla and Skich Announce Strategic Partnership to Bring Merchant of Record Payments to an Alternative Mobile Game Marketplace14.5.2026 19:00:00 EEST | Press release
Xsolla, a leading global video game commerce company, today announced a strategic partnership with Skich, an alternative mobile game marketplace operating on iOS in the EU under Apple's Digital Markets Act provisions and on Android globally. Under the agreement, Xsolla will serve as Merchant of Record for in-app purchases and paid game sales distributed through the Skich Store. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260514867730/en/ Graphic: Xsolla Skich serves as an alternative to traditional mobile storefronts, offering developers a way to reach players outside platform-controlled distribution channels. The partnership with Xsolla enables Skich to offer a fully compliant payment and commerce layer, with Xsolla managing payment processing, tax collection, refunds, and regulatory compliance on behalf of developers, removing a significant operational and legal barrier for studios looking to distribute through alternat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom